These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30152216)

  • 1. [Development of new anti-tuberculosis drugs: the strategy of unconventional microbial culture and silencing gene activation].
    Teng T; Xie L; Xie J
    Sheng Wu Gong Cheng Xue Bao; 2018 Aug; 34(8):1306-1315. PubMed ID: 30152216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent progress in the drug development of coumarin derivatives as potent antituberculosis agents.
    Keri RS; Sasidhar BS; Nagaraja BM; Santos MA
    Eur J Med Chem; 2015 Jul; 100():257-69. PubMed ID: 26112067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential of marine natural Products: Recent Advances in the discovery of Anti-Tuberculosis agents.
    Peng X; Zeng Z; Hassan S; Xue Y
    Bioorg Chem; 2024 Oct; 151():107699. PubMed ID: 39128242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent developments of coumarin-containing derivatives and their anti-tubercular activity.
    Hu YQ; Xu Z; Zhang S; Wu X; Ding JW; Lv ZS; Feng LS
    Eur J Med Chem; 2017 Aug; 136():122-130. PubMed ID: 28494250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-tuberculosis lead molecules from natural products targeting Mycobacterium tuberculosis ClpC1.
    Lee H; Suh JW
    J Ind Microbiol Biotechnol; 2016 Mar; 43(2-3):205-12. PubMed ID: 26586403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of (-)-deoxypergularinine, on its own and in combination with anti-tubercular drugs, against resistant strains of Mycobacterium tuberculosis.
    Nam KW; Jang WS; Jyoti MA; Kim S; Lee BE; Song HY
    Phytomedicine; 2016 May; 23(5):578-82. PubMed ID: 27064017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of line probe assay to BACTEC MGIT 960 system for susceptibility testing of first and second-line anti-tuberculosis drugs in a referral laboratory in South Africa.
    Maningi NE; Malinga LA; Antiabong JF; Lekalakala RM; Mbelle NM
    BMC Infect Dis; 2017 Dec; 17(1):795. PubMed ID: 29282012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A model to predict anti-tuberculosis activity: value proposition for marine microorganisms.
    Liu M; Grkovic T; Zhang L; Liu X; Quinn RJ
    J Antibiot (Tokyo); 2016 Aug; 69(8):594-9. PubMed ID: 27406906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural products as leads for tuberculosis drug development.
    Salomon CE; Schmidt LE
    Curr Top Med Chem; 2012; 12(7):735-65. PubMed ID: 22283816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The future for early-stage tuberculosis drug discovery.
    Zuniga ES; Early J; Parish T
    Future Microbiol; 2015; 10(2):217-29. PubMed ID: 25689534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naphthoquinones isolated from Diospyros anisandra exhibit potent activity against pan-resistant first-line drugs Mycobacterium tuberculosis strains.
    Uc-Cachón AH; Borges-Argáez R; Said-Fernández S; Vargas-Villarreal J; González-Salazar F; Méndez-González M; Cáceres-Farfán M; Molina-Salinas GM
    Pulm Pharmacol Ther; 2014 Feb; 27(1):114-20. PubMed ID: 23968826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress in resistance mechanisms and diagnosis of non-first line anti-TB drugs.
    Liu Y; Wang BX; Liu ZY; Han Y; Tan YJ; Li XJ; Liu JX; Tan S; Zhang TY
    Yi Chuan; 2016 Oct; 38(10):928-939. PubMed ID: 27806934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tuberculosis and its Treatment: An Overview.
    Bansal R; Sharma D; Singh R
    Mini Rev Med Chem; 2018; 18(1):58-71. PubMed ID: 27553018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review on emergence of drug-resistant tuberculosis (MDR & XDR-TB) and its molecular diagnosis in Ethiopia.
    Saravanan M; Niguse S; Abdulkader M; Tsegay E; Hailekiros H; Gebrekidan A; Araya T; Pugazhendhi A
    Microb Pathog; 2018 Apr; 117():237-242. PubMed ID: 29486274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-Target Antitubercular Drugs.
    de Oliveira Viana J; Ishiki HM; Scotti MT; Scotti L
    Curr Top Med Chem; 2018; 18(9):750-758. PubMed ID: 29807515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic diversity of Mycobacterium tuberculosis isoniazid monoresistant and multidrug-resistant in Rio Grande do Sul, a tuberculosis high-burden state in Brazil.
    Esteves LS; Dalla Costa ER; Vasconcellos SEG; Vargas A; Ferreira Junior SLM; Halon ML; Ribeiro MO; Rodenbusch R; Gomes HM; Suffys PN; Rossetti MLR
    Tuberculosis (Edinb); 2018 May; 110():36-43. PubMed ID: 29779771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-line anti-tuberculosis drug resistance and its genetic determinants in multidrug-resistant Mycobacterium tuberculosis clinical isolates.
    Bakuła Z; Napiórkowska A; Kamiński M; Augustynowicz-Kopeć E; Zwolska Z; Bielecki J; Jagielski T
    J Microbiol Immunol Infect; 2016 Jun; 49(3):439-44. PubMed ID: 26117528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beijing genotype of Mycobacterium tuberculosis is significantly associated with linezolid resistance in multidrug-resistant and extensively drug-resistant tuberculosis in China.
    Zhang Z; Pang Y; Wang Y; Liu C; Zhao Y
    Int J Antimicrob Agents; 2014 Mar; 43(3):231-5. PubMed ID: 24439458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.